Francisco José González

Francisco José González


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JFJose Ignacio Fortea
Jose Ignacio Fortea
APANGELA PUENTE
ANGELA PUENTE
ACAntonio Cuadrado
Antonio Cuadrado
PHPatricia Huelin
Patricia Huelin
RPRaúl Pellón
Raúl Pellón
EFEmilio Fábrega
Emilio Fábrega
Liver disease resulting from heart failure (HF) has generally been referred as “cardiac hepatopathy”. One of its main forms is congestive hepatopathy (CH), which results from passive venous congestion in the setting of chronic right-sided HF. The current spectrum of CH differs from earlier reports with HF, due to ischemic cardiomyopathy and congenital heart disease having surpassed rheumatic valvular disease. The chronic passive congestion leads to sinusoidal hypertension, centrilobular fibrosis, and ultimately, cirrhosis (“cardiac cirrhosis”) and hepatocellular carcinoma after several decades of ongoing injury. Contrary to primary liver diseases, in CH, inflammation seems to play no role in the progression of liver fibrosis, bridging fibrosis occurs between central veins to produce a “reversed lobulation” pattern and the performance of non-invasive diagnostic tests of liver fibrosis is poor. Although the clinical picture and prognosis is usually dominated by the underlying heart condition, the improved long-term survival of cardiac patients due to advances in medical and surgical treatments are responsible for the increased number of liver complications in this setting. Eventually, liver disease could become as clinically relevant as cardiac disease and further complicate its management.

30 October 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AOAitor Odriozola**
Aitor Odriozola**
ÁPÁngela Puente
Ángela Puente
ACAntonio Cuadrado
Antonio Cuadrado
CRCoral Rivas
Coral Rivas
ÁAÁngela Anton
Ángela Anton
JFJose Ignacio Fortea
Jose Ignacio Fortea
Portal vein thrombosis constitutes the most common thrombotic event in patients with cirrhosis, with increased rates in the setting of advanced liver disease. Despite being a well-known complication of cirrhosis, the contribution of portal vein thrombosis to hepatic decompensation and overall mortality is still a matter of debate. The incorporation of direct oral anticoagulants and new radiological techniques for portal vein recanalization have expanded our therapeutic arsenal. However, the lack of large prospective observational studies and randomized trials explain the heterogenous diagnostic and therapeutic recommendations of current guidelines. This article seeks to make a comprehensive review of the pathophysiology, clinical features, diagnosis, and treatment of portal vein thrombosis in patients with cirrhosis.

31 August 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JFJose Ignacio Fortea
Jose Ignacio Fortea
ICInés García Carrera
Inés García Carrera
ÁPÁngela Puente
Ángela Puente
ACAntonio Cuadrado
Antonio Cuadrado
PHPatricia Huelin
Patricia Huelin
EFEmilio Fábrega
Emilio Fábrega
In patients with liver cirrhosis the contribution of inherited and acquired prothrombotic disorders in the development of non-malignant portal vein thrombosis (PVT) is inconclusive. The purpose of this retrospective study was to examine the prevalence of thrombophilia in this setting at our center from January 2012 to November 2019. Tests included gene mutational analysis for Factor V Leiden, prothrombin G20210A, JAK2 (V617F), Calreticulin (CARL), in addition to activated protein C resistance, antithrombin III, protein C and S levels, and antiphospholipid antibodies. We included 77 patients, six of whom (7.8%) had a thrombophilic disorder: antiphospholipid syndrome in four patients, prothrombin gene mutation in one and factor V Leiden mutation in one. This latter patient had also been diagnosed with polycythemia vera years before PVT development. Complete thrombosis of the main portal vein and re-thrombosis after stopping anticoagulation were more frequent in patients with thrombophilia, but the rates of recanalization under anticoagulant therapy were similar among groups. No other difference was accounted between groups. The low prevalence of acquired and inherited thrombophilia found in patients with cirrhosis and PVT support testing for these disorders on an individual basis and avoiding universal screening to reduce costs and unwarranted testing.

9 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
EUElena Urizar
Elena Urizar
VBVíctor Domínguez Beltrán
Víctor Domínguez Beltrán
CMCarmelo Morales Morales-Angulo
Carmelo Morales Morales-Angulo
NPNuria Puente
Nuria Puente
PSPablo Solís Sánchez
Pablo Solís Sánchez
Jose RianchoJose Riancho
Jose Riancho
Background: Hereditary hemorrhagic telangiectasia (HHT) shows substantial phenotypic variability. We investigated genotype-phenotype associations, focusing on variant type and predicted effects on RNA processing. Methods: We conducted a retrospective observational study of genetically confirmed HHT patients carrying ENG or ACVRL1 variants. Clinical manifestations, epistaxis severity, treatment and genetic characteristics were assessed. Variants were classified according to molecular type and predicted RNA-disrupting effect. Results: Seventy-eight patients were included, 28 carrying ENG and 50 ACVRL1 variants. Pulmonary arteriovenous malformations (PAVMs) were more frequent among ENG than ACVRL1 carriers (53.6% vs. 24.0%, p = 0.024), whereas hepatic AVMs showed a nonsignificant predominance in ACVRL1 (44.0% vs. 21.4%, p = 0.072). Moderate-to-severe recent epistaxis was more frequent among ACVRL1 carriers (34.0% vs. 3.6%, p = 0.014). Overall, PAVMs were more frequent in patients carrying RNA-disruptive variants than in those with non-RNA-disruptive variants (60.9% vs. 23.6%, p = 0.004). Importantly, this association persisted within ENG, with PAVMs occurring in 73.7% of patients with RNA-disruptive variants compared with 11.1% of those with non-RNA-disruptive variants (p = 0.004). Among patients with non-RNA-disruptive variants, cerebral vascular malformations were more frequent in ENG than in ACVRL1 carriers (44.4% vs. 8.7%, p = 0.013). Conclusions: Beyond established ENG-ACVRL1 phenotypic differences, variant-level molecular characteristics may contribute to HHT phenotypic heterogeneity.